RSV IMMUNOGENS, ANTIBODIES AND COMPOSITIONS THEREOF

• US 20120315270A1
• Filed: 10/21/2010
• Published: 12/13/2012
• Est. Priority Date: 10/21/2009
• Status: Abandoned Application

• Current Assignee: The United States of America As Represented By The Secretary of Agriculture, United States Incorporated, University of Washington
• Original Assignee: The United States of America As Represented By The Secretary of Agriculture, United States Incorporated, University of Washington
• Inventors: Kwong, Peter D., Graham, Barney S., Schief, William R., McLellan, Jason S., Jardine, Joe, Correia, Bruno, Chen, Man
• Application Number:
  US13/502,595
• Publication Number:
  US 20120315270A1
• Time in Patent Office: Days
• US Class Current: 424/133.1
• CPC Class Codes: A61K 2039/55561 CpG containing adjuvants; Oligonucleotide containing adjuvants
• CPC Class Codes: A61K 2039/57 characterised by the type of response, e.g. Th1, Th2
• CPC Class Codes: A61K 2039/645 Dendrimers; Multiple antigen peptides
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/155 Paramyxoviridae, e.g. parainfluenza virus
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 16/1027 Paramyxoviridae, e.g. respiratory syncytial virus
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C12N 2760/18522 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2760/18534 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

The present invention provides immunogens that protect against RSV infection. The present invention also provides antibody proteins that protect against RSV infection. Such immunogens and antibody proteins are produced based on three-dimensional models also included in the invention. One model is of a complex between motavizumab and its antibody-binding domain on RSV fusion (F) protein. A second model is of a complex between 10 IF antibody and its antibody-binding domain on RSV F protein. The immunogens disclosed herein have been modified to elicit a humoral response against RSV F protein without eliciting a significant cell-mediated response against RSV. Such immunogens can comprise a scaffold into which RSV contact residues are embedded. The present invention also includes methods that utilize the disclosed three-dimensional models to produce immunogens and antibody proteins of the present invention. Also disclosed are methods of using the disclosed immunogens, for example to protect individuals from RSV infection. Also disclosed are methods of using the disclosed antibody proteins, for example to protect individuals from RSV infection.

Claims

1. An RSV immunogen comprising an amino acid sequence of 1LP1_b (SEQ ID NO:

11) having from one to twenty amino acid substitutions, wherein at least one amino acid substitution is selected from the group consisting of;

(a) substitution of a serine at amino acid position N-25 in SEQ ID NO;

11;

(b) substitution of a leucine at amino acid position I-28 in SEQ ID NO;

11;

(c) substitution of a serine at amino acid position Q-29 in SEQ ID NO;

11;

(d) substitution of an isoleucine at amino acid position L-31 in SEQ ID NO;

11;

(e) substitution of an asparagine at amino acid position K-32 in SEQ ID NO;

11;

(f) substitution of an aspartic acid at amino acid position K-4 in SEQ ID NO;

11;

(g) substitution of a lysine at amino acid position Q-6 in SEQ ID NO;

11;

(h) substitution of a lysine at amino acid position Q-7 in SEQ ID NO;

11;

(i) substitution of a leucine at amino acid position N-8 in SEQ ID NO;

11;

(j) substitution of a serine at amino acid position F-10 in SEQ ID NO;

11; and

(k) substitution of an asparagine at amino acid position Y-11 in SEQ ID NO;

11.

3. The RSV immunogen of claim 1, wherein said RSV immunogen comprises an amino acid sequence that is at least 95% identical to an amino acid sequence of a protein selected from the group consisting of 1lp1b_—

001 (SEQ ID NO;

18), 1lp1b_—

002 (SEQ ID NO;

21), 1lp1b_—

003 (SEQ ID NO;

24), and 1lp1b_—

004 (SEQ ID NO;

149).

4. The RSV immunogen of claim 1, wherein said RSV immunogen comprises an amino acid sequence of a protein selected from the group consisting of 1lp1b_—

001 (SEQ ID NO;

18), 1lp1b_—

002 (SEQ ID NO;

21), 1lp1b_—

003 (SEQ ID NO;

24), 1lp1b_—

004 (SEQ ID NO;

149), mota_—

1lp1b.m1.c1.d1_glyc1 (SEQ ID NO;

55), mota_—

1lp1b.m1.c1.d1_glyc2 (SEQ ID NO;

56), 1lp1b_—

003_Glyc1 (SEQ ID NO;

39), 1lp1b_—

003_Glyc2 (SEQ ID NO;

42), 1lp1b_—

003_Glyc3 (SEQ ID NO;

45), 1lp1b_—

003_Glyc4 (SEQ ID NO;

48), 1lp1b_—

003_Glyc5 (SEQ ID NO;

51), 1lp1b_—

003_Glyc6 (SEQ ID NO;

54), mota_—

1lp1b.m1.c1.d1_des1_—

1 (SEQ ID NO;

66), mota_—

1lp1b.m1.c1.d1_des1_—

2 (SEQ ID NO;

67), mota_—

1lp1b.m1.c1.d1_des1_—

3 (SEQ ID NO;

68 mota_—

1lp1b.m1.c1.d1_des1_—

5 (SEQ ID NO;

69), mota_—

1lp1b.m1.c1.d1_des1_—

6 (SEQ ID NO;

70), mota_—

1lp1b.m1.c1.d1_des1_—

7 (SEQ ID NO;

71), mota_—

1lp1b.m1.c1.d1_des1_—

8 (SEQ ID NO;

72), mota_—

1lp1b.m1.c1.d1_des1_—

9 (SEQ ID NO;

73), mota_—

1lp1b.m1.c1.d1_des1_—

10 (SEQ ID NO;

74), mota_—

1lp1b.m1.c1.d1_des1_—

11 (SEQ ID NO;

75), 1lp1b_—

003_Surf1 (SEQ ID NO;

59), 1lp1b_—

003_Surf6 (SEQ ID NO;

62), 1lp1b_—

003_Surf8 (SEQ ID NO;

65), 1lp1b_—

003_ferritin (SEQ ID NO;

138), 1lp1b_—

003_eumS (SEQ ID NO;

140), 1lp1b_—

003_eumSP (SEQ ID NO;

142), 1lp1b_—

003_eumL (SEQ ID NO;

144), 1lp1b_—

003_eumLP (SEQ ID NO;

146), 1lp1b_—

003_K46A (SEQ ID NO;

78), 1lp1b_—

003_Q52A (SEQ ID NO;

81), 1lp1b_—

003_I13L_F27A (SEQ ID NO;

87), 1lp1b_—

003_L41I_L42V (SEQ ID NO;

90), 1lp1b_—

003_L41I_L42A (SEQ ID NO;

93), lp1b_—

003_I13A (SEQ ID NO;

105), 1lp1b_—

003_L16A (SEQ ID NO;

108), 1lp1b_—

003_F27A (SEQ ID NO;

111), 1lp1b_—

003_L41A (SEQ ID NO;

114), 1lp1b_—

003_L42A (SEQ ID NO;

117), and 1lp1b_—

003_Neg1 (SEQ ID NO;

132).

15. The RSV immunogen of claim 1, wherein said RSV immunogen comprises at least one characteristic selected from the group consisting of binding a motavizumab antibody, eliciting a humoral immune response against RSV and failing to elicit a cellular immune response.

19. The RSV immunogen of claim 1, wherein said RSV immunogen has a motavizumab antibody-binding domain comprising less than 9 consecutive amino acids from a motavizumab antibody-binding domain of RSV fusion protein.

21. A nucleic acid molecule comprising a nucleic acid sequence that encodes an immunogen of claim 1.

27. A method selected from the group consisting of a method to elicit a neutralizing humoral immune response against RSV and a method to protect a patient from RSV infection, said method comprising administering an RSV immunogen of claim 1.

2. (canceled)

5-10. -10. (canceled)

11. An RSV immunogen comprising an amino acid sequence of truncated 1S2X_a (SEQ ID NO:

13) having from one to twenty-five amino acid substitutions, wherein at least one amino acid substitution is selected from the group consisting of;

(a) substitution of a serine at amino acid position 92 in SEQ ID NO;

13;

(b) substitution of a leucine at amino acid position 95 in SEQ ID NO;

13;

(c) substitution of a serine at amino acid position 96 in SEQ ID NO;

13;

(d) substitution of an isoleucine at amino acid position 98 in SEQ ID NO;

13;

(e) substitution of an asparagine at amino acid position 99 in SEQ ID NO;

13;

(f) substitution of an aspartic acid at amino acid position 100 in SEQ ID NO;

13;

(g) substitution of an asparagine at amino acid position 105 in SEQ ID NO;

13;

(h) substitution of an aspartic acid at amino acid position 106 in SEQ ID NO;

13;

(i) substitution of a lysine at amino acid position 108 in SEQ ID NO;

13;

(j) substitution of a lysine at amino acid position 109 in SEQ ID NO;

13;

(k) substitution of a leucine at amino acid position 110 in SEQ ID NO;

13;

(l) substitution of a serine at amino acid position 112 in SEQ ID NO;

13; and

(m) substitution of an asparagine at amino acid position 113 in SEQ ID NO;

13.

13. The RSV immunogen of claim 11, wherein said RSV immunogen comprises an amino acid sequence that is at least 95% identical to an amino acid sequence of a protein selected from the group consisting of 1s2xa_—

001 (SEQ ID NO;

152), 1s2xa_—

002 (SEQ ID NO;

155), 1s2xa_—

003 (SEQ ID NO;

158), and 1s2xa_—

004 (SEQ ID NO;

164).

14. The RSV immunogen of claim 11, wherein said RSV immunogen comprises an amino acid sequence of a protein selected from the group consisting of 1s2xa_—

001 (SEQ ID NO;

152), 1s2xa_—

002 (SEQ ID NO;

155), 1s2xa_—

003 (SEQ ID NO;

158), and 1s2xa_—

004 (SEQ ID NO;

164).

20. A nucleic acid molecule comprising a nucleic acid sequence that encodes an immunogen of claim 11.

12. (canceled)

16-18. -18. (canceled)

22-26. -26. (canceled)

28. (canceled)

29. An immunogen comprising an antibody-binding domain that binds an antibody selected from the group consisting of motavizumab and 101F antibody,

wherein the three-dimensional structure of said antibody-binding domain of said immunogen spatially corresponds to a three-dimensional structure of an antibody-binding domain of a fusion (F) peptide derived from respiratory syncytial virus (RSV) fusion (F) protein in a complex selected from the group consisting of:

(a) a complex between a F peptide consisting of amino acid sequence SEQ ID NO;

2 and motavizumab, said complex being set forth in the three-dimensional model defined by the atomic coordinates specified in Protein Data Bank accession code 3IXT; and

(b) a complex between a F peptide consisting of amino acid sequence SEQ ID NO;

4 and 101F antibody, said complex being set forth in the three-dimensional model defined by the atomic coordinates specified in Protein Data Bank accession code 3O41;

wherein said antibody-binding domain of said immunogen comprises less than 12 consecutive amino acids from a motavizumab-binding domain or a 101F antibody-binding domain of RSV F protein, and wherein said immunogen elicits a humoral immune response against RSV.

30. The immunogen of claim 29, wherein said antibody-binding domain of said immunogen comprises contact residues selected from the group consisting of:

(a) contact residues that have a spatial orientation represented by atomic coordinates that have a root mean square deviation of protein backbone atoms of less than 10 angstroms from the corresponding backbone atoms of contact residues in an RSV F peptide that contacts motavizumab or 101F antibody in a complex set forth in claim 29;

(b) contact residues of the motavizumab-binding domain embedded in a protein scaffold comprising a three-dimensional structure having two alpha helices defined by atomic coordinates that have a root mean square deviation of protein backbone atoms of less than 10 angstroms when superimposed on the two alpha helices of the peptide consisting of amino acid sequence SEQ ID NO;

2 when complexed with motavizumab, the three-dimensional model of said complex being defined by the coordinates specified in Protein Data Bank accession code 3IXT; and

,

(c) contact residues of the 101F antibody-binding domain embedded in a protein scaffold comprising a three-dimensional structure with atomic coordinates that have a root mean square deviation of protein backbone atoms of less than 10 angstroms when superimposed on the peptide consisting of amino acid sequence SEQ ID NO;

4 when complexed with 101F antibody, the 3-dimensional model of said complex being defined by the coordinates specified in Protein Data Bank accession code 3O41.

34. An RSV immunogen of claim 29, wherein said antibody-binding domain of said immunogen comprises less than 9 consecutive amino acids from a motavizumab-binding domain or a 101F antibody-binding domain of RSV F protein.

35. The immunogen of claim 29, wherein the motavizumab-binding domain of said immunogen comprises less than 15 amino acids of the motavizumab-binding domain from said RSV F peptide, wherein said amino acids are in clusters of no more than 8 consecutive amino acids per cluster.

37. The immunogen of claim 29, wherein the 101F antibody-binding domain of said immunogen comprises no more than 10 amino acids of the 101F antibody-binding domain of said RSV F peptide, wherein said amino acids are in clusters of no more than 8 consecutive amino acids per cluster.

39. The immunogen of claim 29, wherein said immunogen comprises an amino acid sequence of a protein selected from the group consisting of 1LP1_b (SEQ ID NO:

11), 1S2X_a (SEQ ID NO;

12), truncated 1S2X_a (SEQ ID NO;

13), and 2EIA_a (SEQ ID NO;

14).

40. The immunogen of claim 29, wherein said immunogen comprises an amino acid sequence selected from the group consisting of 1LP1_b (SEQ ID NO:

11), 1S2X_a (SEQ ID NO;

12), truncated 1S2X_a (SEQ ID NO;

13), and 2EIA_a (SEQ ID NO;

14), wherein said amino acid sequence comprises at least one substitution selected from the group consisting of;

(a) substitution of a serine for the amino acid spatially corresponding to the amino acid at position 2 of SEQ ID NO;

2;

(b) substitution of a leucine for the amino acid spatially corresponding to the amino acid at position 5 of SEQ ID NO;

2;

(c) substitution of a serine for the amino acid spatially corresponding to the amino acid at position 6 of SEQ ID NO;

2;

(d) substitution of an isoleucine for the amino acid spatially corresponding to the amino acid at position 8 of SEQ ID NO;

2;

(e) substitution of an asparagine for the amino acid spatially corresponding to the amino acid at position 9 of SEQ ID NO;

2;

(f) substitution of an aspartic acid for the amino acid spatially corresponding to the amino acid at position 10 of SEQ ID NO;

2;

(g) substitution of a threonine for the amino acid spatially corresponding to the amino acid at position 14 of SEQ ID NO;

2;

(h) substitution of an asparagine for the amino acid spatially corresponding to the amino acid at position 15 of SEQ ID NO;

2;

(i) substitution of an aspartic acid for the amino acid spatially corresponding to the amino acid at position 16 of SEQ ID NO;

2;

(j) substitution of a lysine for the amino acid spatially corresponding to the amino acid at position 18 of SEQ ID NO;

2;

(k) substitution of a lysine for the amino acid spatially corresponding to the amino acid at position 19 of SEQ ID NO;

2;

(l) substitution of a leucine for the amino acid spatially corresponding to the amino acid at position 20 of SEQ ID NO;

2;

(m) substitution of a serine for the amino acid spatially corresponding to the amino acid at position 22 of SEQ ID NO;

2; and

(n) substitution of an asparagine for the amino acid spatially corresponding to the amino acid at position 23 of SEQ ID NO;

2.

42. The immunogen of claim 30, wherein said protein scaffold comprises an amino acid sequence comprising at least one substitution selected from the group consisting of:

(a) substitution of a lysine for the amino acid spatially corresponding to the amino acid at position 1 of SEQ ID NO;

4;

(b) substitution of an arginine for the amino acid spatially corresponding to the amino acid at position 3 of SEQ ID NO;

4;

(c) substitution of a isoleucine for the amino acid spatially corresponding to the amino acid at position 5 of SEQ ID NO;

4;

(d) substitution of a isoleucine for the amino acid spatially corresponding to the amino acid at position 6 of SEQ ID NO;

4;

(e) substitution of a lysine for the amino acid spatially corresponding to the amino acid at position 7 of SEQ ID NO;

4;

(f) substitution of a threonine for the amino acid spatially corresponding to the amino acid at position 8 of SEQ ID NO;

4;

(g) substitution of a phenylalanine for the amino acid spatially corresponding to the amino acid at position 9 of SEQ ID NO;

4; and

,

(h) substitution of a serine for the amino acid spatially corresponding to the amino acid at position 10 of SEQ ID NO;

4.

44. The immunogen of claim 29, wherein said immunogen comprises an amino acid sequence of a protein selected from the group consisting of 1lp1b_—

001 (SEQ ID NO;

18), 1lp1b_—

002 (SEQ ID NO;

21), 1lp1b_—

003 (SEQ ID NO;

24), 1lp1b_—

004 (SEQ ID NO;

149), 1s2xa_—

001 (SEQ ID NO;

152), 1s2xa_—

002 (SEQ ID NO;

155), 1s2xa_—

003 (SEQ ID NO;

158), 1s2xa_—

004 (SEQ ID NO;

164), 2eiaa_—

001 (SEQ ID NO;

167), 2eiaa_—

002 (SEQ ID NO;

170), mota_—

1lp1b.m1.c1.d1_glyc1 (SEQ ID NO;

55), mota_—

1lp1b.m1.c1.d1_glyc2 (SEQ ID NO;

56), 1lp1b_—

003_Glyc1 (SEQ ID NO;

39), 1lp1b_—

003_Glyc2 (SEQ ID NO;

42), 1lp1b_—

003_Glyc3 (SEQ ID NO;

45), 1lp1b_—

003_Glyc4 (SEQ ID NO;

48), 1lp1b_—

003_Glyc5 (SEQ ID NO;

51), 1lp1b_—

003_Glyc6 (SEQ ID NO;

54), mota_—

1lp1b.m1.c1.d1_des1_—

1 (SEQ ID NO;

66), mota_—

1lp1b.m1.c1.d1_des1_—

2 (SEQ ID NO;

67), mota_—

1lp1b.m1.c1.d1_des1_—

3 (SEQ ID NO;

68), mota_—

1lp1b.m1.c1.d1_des1_—

5 (SEQ ID NO;

69), mota_—

1lp1b.m1.c1.d1_des1_—

6 (SEQ ID NO;

70), mota_—

1lp1b.m1.c1.d1_des1_—

7 (SEQ ID NO;

71), mota_—

1lp1b.m1.c1.d1_des1_—

8 (SEQ ID NO;

72), mota_—

1lp1b.m1.c1.d1_des1_—

9 (SEQ ID NO;

73), mota_—

1lp1b.m1.c1.d1_des1_—

10 (SEQ ID NO;

74), mota_—

1lp1b.m1.c1.d1_des1_—

11 (SEQ ID NO;

75), 1lp1b_—

003_Surf1 (SEQ ID NO;

59), 1lp1b_—

003_Surf6 (SEQ ID NO;

62), and 1lp1b_—

003_Surf8 (SEQ ID NO;

65), 1lp1b_—

003_ferritin (SEQ ID NO;

138), 1lp1b_—

003_eumS (SEQ ID NO;

140), 1lp1b_—

003_eumSP (SEQ ID NO;

142), 1lp1b_—

003_eum_L (SEQ ID NO;

144), 1lp1b_—

003eum_LP (SEQ ID NO;

146), 1lp1b_—

003_K46A (SEQ ID NO;

78), 1lp1b_—

003_Q52A (SEQ ID NO;

81), 1lp1b_—

003_I13L_F27A (SEQ ID NO;

87), 1lp1b_—

003_L41I_L42V (SEQ ID NO;

90), 1lp1b-003_L41I_L42A (SEQ ID NO;

93), 1lp1b_—

003_I13A (SEQ ID NO;

105), 1lp1b_—

003_L16A (SEQ ID NO;

108), 1lp1b_—

003_F27A (SEQ ID NO;

111), 1lp1b_—

003_L41A (SEQ ID NO;

114), 1lp1b_—

003_L42A (SEQ ID NO;

117), and 1lp1b_—

003_Neg1 (SEQ ID NO;

132).

50. The RSV immunogen of claim 29, wherein said immunogen elicits a humoral immune response against RSV, but not a cellular immune response.

52. A nucleic acid molecule comprising a nucleic acid sequence that encodes an immunogen of claim 29.

60. A method selected from the group consisting of:

(a) a method to elicit a neutralizing humoral immune response against RSV and,

(b) a method to protect a patient from RSV infection, said method comprising administering an RSV immunogen of claim 29.

31-33. -33. (canceled)

36. (canceled)

38. (canceled)

41. (canceled)

43. (canceled)

45-49. -49. (canceled)

51. An immunogen comprising a protein comprising an amino acid sequence of a protein selected from the group consisting of RSV F₀ Fd (SEQ ID NO:

174), RSV F Fd (SEQ ID NO;

175), and RSV F0 Fd GAG (SEQ ID NO;

176).

53-59. -59. (canceled)

61. (canceled)

62. An antibody protein selected from the group consisting of:

A) an antibody protein comprising a heavy chain comprising SEQ ID NO;

5, except that said antibody protein comprises at least one amino acid substitution selected from the group consisting of;

(a) substitution of the amino acid corresponding to position 32 of SEQ ID NO;

5, is a histidine or a glutamic acid;

(b) substitution of the amino acid at position 35 of SEQ ID NO;

5 is substituted with an alanine;

(c) substitution of the amino acid at position 52 of SEQ ID NO;

5 is substituted with an amino acid selected from the group consisting of lysine, histidine, threonine, serine and arginine;

(d) substitution of the amino acid at position 53 of SEQ ID NO;

5 is substituted with a histidine or a serine;

(e) substitution of the amino acid at position 54 of SEQ ID NO;

5 is substituted with a phenylalanine or an arginine;

(f) substitution of the amino acid at position 56 of SEQ ID NO;

5 is substituted with an amino acid selected from the group consisting of isoleucine, serine, glutamic acid, and aspartic acid;

(g) substitution of the amino acid at position 58 of SEQ ID NO;

5 is substituted with a tyrosine or a tryptophan;

(h) substitution of the amino acid at position 97 of SEQ ID NO;

5 is substituted with an aspartic acid, a histidine or an arginine;

(i) substitution of the amino acid at position 99 of SEQ ID NO;

5 is substituted with aspartic acid;

(j) substitution of the amino acid at position 100 of SEQ ID NO;

5 is substituted with a tyrosine, a tryptophan or a histidine; and

(k) substitution of the amino acid at position 100A of SEQ ID NO;

5 is substituted with a serine or a threonine; and

,

B). an antibody protein comprising a heavy chain comprising SEQ ID NO;

6, except that said antibody protein comprises at least one amino acid substitution selected from the group consisting of;

(a) substitution of the amino acid at position 32 of SEQ ID NO;

6 is substituted with a phenylalanine;

(b) substitution of the amino acid at position 49 of SEQ ID NO;

6 is substituted with a histidine or an arginine;

(c) substitution of the amino acid at position 92 of SEQ ID NO;

6 is substituted with a lysine;

(d) substitution of the amino acid at position 94 of SEQ ID NO;

6 is substituted with a histidine; and

(e) substitution of the amino acid at position 96 of SEQ ID NO;

6 is substituted with a histidine.

64. A nucleic acid molecule comprising a nucleic acid sequence that encodes an antibody protein of claim 62.

69. A method to protect a patient from RSV infection comprising administering to said patient an antibody protein of claim 62, wherein said administration protects said patient from RSV infection.

63. (canceled)

65-68. -68. (canceled)